Compared to myocardial ischemia-reperfusion (IR) or VA-ECMO support for 30 min before reperfusion, Impella CP device activation before reperfusion reduced myocardial infarct size (51 ± 14% vs 62 ± 15% vs 33 ± 7%, IR, VA-ECMO, Impella, respectively, p < 0.05 for Impella vs either group; Fig. 1b). The gene discussed is CP; the disease is myocardial infarction.